PT1083879E - Metodos e dispositivos para proporcionar uma terapia de drogas prolongada - Google Patents

Metodos e dispositivos para proporcionar uma terapia de drogas prolongada

Info

Publication number
PT1083879E
PT1083879E PT99955212T PT99955212T PT1083879E PT 1083879 E PT1083879 E PT 1083879E PT 99955212 T PT99955212 T PT 99955212T PT 99955212 T PT99955212 T PT 99955212T PT 1083879 E PT1083879 E PT 1083879E
Authority
PT
Portugal
Prior art keywords
methods
devices
drug therapy
prolonged drug
drug
Prior art date
Application number
PT99955212T
Other languages
English (en)
Inventor
Richard G Weyers
Suneel K Gupta
Padmaja Shivanand
Jeri D Wright
Lawrence G Hamel
Carol A Christopher
Samuel R Saks
Atul D Ayer
Diane R Guinta
Hatamkhany Zahedeh
Andrew C Lam
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/253,317 external-priority patent/US6919373B1/en
Application filed by Alza Corp filed Critical Alza Corp
Publication of PT1083879E publication Critical patent/PT1083879E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/88—Investigating the presence of flaws or contamination
    • G01N21/95—Investigating the presence of flaws or contamination characterised by the material or shape of the object to be examined
    • G01N21/9508—Capsules; Tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99955212T 1998-06-03 1999-05-27 Metodos e dispositivos para proporcionar uma terapia de drogas prolongada PT1083879E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8778798P 1998-06-03 1998-06-03
US09/253,317 US6919373B1 (en) 1996-11-12 1999-02-19 Methods and devices for providing prolonged drug therapy

Publications (1)

Publication Number Publication Date
PT1083879E true PT1083879E (pt) 2005-01-31

Family

ID=26777397

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99955212T PT1083879E (pt) 1998-06-03 1999-05-27 Metodos e dispositivos para proporcionar uma terapia de drogas prolongada

Country Status (16)

Country Link
EP (2) EP1083879B1 (pt)
JP (1) JP2002516848A (pt)
KR (1) KR20080083074A (pt)
CN (1) CN1209098C (pt)
AT (1) ATE277594T1 (pt)
AU (1) AU4319799A (pt)
CA (1) CA2333688A1 (pt)
DE (1) DE69920689T2 (pt)
DK (1) DK1083879T3 (pt)
ES (1) ES2229783T3 (pt)
HK (2) HK1035492A1 (pt)
IL (1) IL140020A0 (pt)
NO (1) NO330235B1 (pt)
NZ (1) NZ508567A (pt)
PT (1) PT1083879E (pt)
WO (1) WO1999062496A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE69939748D1 (de) 1998-11-02 2008-11-27 Elan Pharma Int Ltd Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
KR20020072290A (ko) * 2000-01-20 2002-09-14 델시스 파머수티컬 코포레이션 다단계 약물 투여 형태
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
CN1638740A (zh) 2001-09-28 2005-07-13 麦克内尔-Ppc股份有限公司 释出得到修饰的剂型
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
DK1539115T3 (da) * 2002-07-29 2008-01-28 Alza Corp Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
NZ538842A (en) * 2002-09-28 2008-03-28 Mcneil Ppc Inc Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids
GR1004330B (el) * 2002-10-14 2003-09-05 Lavipharm A.E. Φαρμακοτεχνικη μορφη για τη χορηγηση οργανικων νιτρικων ενωσεων
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
JP2006517593A (ja) * 2003-02-11 2006-07-27 アルザ・コーポレーシヨン 投薬形態物の層形状修飾方法およびそのような修飾を受けさせた投薬形態物
EP1708684A2 (en) 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
JP4959335B2 (ja) 2003-10-08 2012-06-20 マリンクロッド エルエルシー メチルフェニデート溶液および関連する投与および製造方法
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
WO2005112897A2 (en) * 2004-05-21 2005-12-01 Accu-Break Technologies, Inc. Immediate release pharmaceutical tablets with height greater than width
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2009023006A2 (en) * 2006-05-08 2009-02-19 Mcneil-Ppc, Inc. Modified release dosage form
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
KR101264961B1 (ko) * 2008-11-07 2013-05-16 주식회사 삼양바이오팜 메칠페니데이트의 방출 제어용 약제학적 조성물
CN102639122A (zh) 2009-12-07 2012-08-15 麦克内尔-Ppc股份有限公司 调释剂型的部分浸渍包衣
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3934622A1 (en) 2019-03-05 2022-01-12 Amneal Complex Products Research LLC Delayed release methylphenidate compositions
CN114681422B (zh) * 2020-12-30 2023-09-05 深圳翰宇药业股份有限公司 一种硝苯地平控释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US6068859A (en) * 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
JP4393587B2 (ja) * 1996-08-16 2010-01-06 アルザ コーポレイション 医薬の上昇性投与量を提供するための薬剤投与型
AU4801497A (en) * 1996-09-30 1998-04-24 Alza Corporation Dosage form and method for administering drug

Also Published As

Publication number Publication date
EP1083879A1 (en) 2001-03-21
CN1352549A (zh) 2002-06-05
ES2229783T3 (es) 2005-04-16
ATE277594T1 (de) 2004-10-15
NO20006007D0 (no) 2000-11-28
CN1209098C (zh) 2005-07-06
DE69920689T2 (de) 2005-02-24
NO330235B1 (no) 2011-03-07
KR20080083074A (ko) 2008-09-12
AU4319799A (en) 1999-12-20
HK1046638B (zh) 2006-02-24
HK1035492A1 (en) 2001-11-30
CA2333688A1 (en) 1999-12-09
EP1449524A1 (en) 2004-08-25
HK1046638A1 (en) 2003-01-24
NO20006007L (no) 2001-02-05
JP2002516848A (ja) 2002-06-11
DK1083879T3 (da) 2005-01-31
DE69920689D1 (de) 2004-11-04
IL140020A0 (en) 2002-02-10
NZ508567A (en) 2004-02-27
EP1083879B1 (en) 2004-09-29
WO1999062496A1 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
PT1083879E (pt) Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
DE1001772T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
NO20053224D0 (no) Patient controlled drug administration device.
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
EP1514105A4 (en) METHOD FOR MODULATING TUBULINDEACETYLASE ACTIVITY
NO20003218D0 (no) Oralfarmasøytisk doseringsform med forlenget frigivningsvirkning
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
DK0998287T3 (da) Anvendelse af levobupivacain
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
PT1190712E (pt) Composicao de esferas de tramadol para administracao oral uma vez por dia
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
GB0201607D0 (en) Formulation for the administration of medicinal substances
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
NO971574D0 (no) Medisinmateanordning for tildeling av medisin via munnen særlig beregnet for mindre barn
DE60234604D1 (de) Orale dosierungsform enthaltend einen therapeutischen wirkstoff und einen gegenwirdenden wirkstoff